FDA, Novocure
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC).
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first tre | Novocure described its Tumor Treating Fields therapy as the first of its kind for the aggressive cancer,
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant survival benefits.
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the [Food and Drug Administration had approved Optune Lua](
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung cancer cells. This innovative technology is based on the use with low intensity and with continuity of electric fields that operate with different frequencies and it has been presented in some clinical trials.
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS improvement.
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
Investor's Business Daily on MSN2d
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...
STAT2d
A controversial approval for Novocure’s device
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
These Stocks Are Moving the Most Today: ASML, Nvidia, United Airlines, J.B. Hunt, DJT, Novocure, Morgan Stanley, and More
Stock futures traded mildly to the upside Wednesday and tech shares looked set for a slight rebound following a sharp slump ...
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...